RenovoRx RNXT Stock
0.99 USD
{{ price }}
-1.980196%
{{change_pct}}%
SECTOR
Healthcare
INDUSTRY
Biotechnology
COUNTRY
United States
Exchange
NasdaqCM
Market Cap
36.91M USD
LOW - HIGH [24H]
0.95
-
1.01 USD
VOLUME [24H]
71.44K USD
{{ volume }}
P/E Ratio
0
Earnings per share
-0.4 USD
RenovoRx Price Chart
RenovoRx RNXT Financial and Trading Overview
| RenovoRx stock price | 0.99 USD |
| Previous Close | 2 USD |
| Open | 2.02 USD |
| Bid | 0 USD x 1300 |
| Ask | 0 USD x 1000 |
| Day's Range | 1.93 - 2.34 USD |
| 52 Week Range | 1.5 - 5.75 USD |
| Volume | 61.8K USD |
| Avg. Volume | 38.2K USD |
| Market Cap | 22.7M USD |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.4 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 11.5 USD |
RNXT Valuation Measures
| Enterprise Value | 16.54M USD |
| Trailing P/E | N/A |
| Forward P/E | -2.8 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 6.27451 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | -1.621 |
Trading Information
RenovoRx Stock Price History
| Beta (5Y Monthly) | N/A |
| 52-Week Change | 12.00% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 5.75 USD |
| 52 Week Low | 1.5 USD |
| 50-Day Moving Average | 2.46 USD |
| 200-Day Moving Average | 2.6 USD |
RNXT Share Statistics
| Avg. Volume (3 month) | 38.2K USD |
| Avg. Daily Volume (10-Days) | 34.5K USD |
| Shares Outstanding | 10.13M |
| Float | 7.34M |
| Short Ratio | 0.92 |
| % Held by Insiders | 17.94% |
| % Held by Institutions | 11.66% |
| Shares Short | 17.55K |
| Short % of Float | 0.20% |
| Short % of Shares Outstanding | 0.16% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -68.93% |
| Return on Equity (ttm) | -128.42% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -10201500 USD |
| Net Income Avi to Common (ttm) | -10143000 USD |
| Diluted EPS (ttm) | -1.13 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 3.72M USD |
| Total Cash Per Share (mrq) | 0.37 USD |
| Total Debt (mrq) | 0 USD |
| Total Debt/Equity (mrq) | N/A |
| Current Ratio (mrq) | 3.307 |
| Book Value Per Share (mrq) | 0.357 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -9420000 USD |
| Levered Free Cash Flow (ttm) | -5409750 USD |
Profile of RenovoRx
| Country | United States |
| State | CA |
| City | Los Altos |
| Address | 4546 El Camino Real |
| ZIP | 94022 |
| Phone | 650 284 4433 |
| Website | https://renovorx.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 10 |
RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. The company was founded in 2009 and is headquartered in Los Altos, California.
Q&A For RenovoRx Stock
What is a current RNXT stock price?
RenovoRx RNXT stock price today per share is 0.99 USD.
How to purchase RenovoRx stock?
You can buy RNXT shares on the NasdaqCM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for RenovoRx?
The stock symbol or ticker of RenovoRx is RNXT.
Which industry does the RenovoRx company belong to?
The RenovoRx industry is Biotechnology.
How many shares does RenovoRx have in circulation?
The max supply of RenovoRx shares is 37.29M.
What is RenovoRx Price to Earnings Ratio (PE Ratio)?
RenovoRx PE Ratio is now.
What was RenovoRx earnings per share over the trailing 12 months (TTM)?
RenovoRx EPS is -0.4 USD over the trailing 12 months.
Which sector does the RenovoRx company belong to?
The RenovoRx sector is Healthcare.
RenovoRx RNXT included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 17382.94 USD — |
+1.26
|
6.5B USD — | 17110.72 USD — | 17404.49 USD — | — - | 6.5B USD — |
| NASDAQ HealthCare IXHC | 923.51 USD — |
-0.73
|
— — | 917.75 USD — | 925.61 USD — | — - | — — |
- {{ link.label }} {{link}}